Retatrutide is a novel triple-agonist investigational drug that targets GLP-1, GIP, and glucagon receptors, being developed by Eli Lilly for the treatment of obesity and type 2 diabetes. In clinical trials, it has shown significant weight loss results, with participants losing up to 24% of their body weight over 48 weeks.
⚠️ Research Use Only: This product is intended strictly for laboratory and in-vitro research purposes only. Not approved for human or veterinary use. Not intended for ingestion, injection, or any form of human or animal consumption. By purchasing, you confirm you are a qualified researcher and will handle this product in accordance with applicable laws and regulations.
Reviews
There are no reviews yet.